Berenberg Bank reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Wednesday. The firm currently has a GBX 5,800 ($76.54) price target on the biopharmaceutical company’s stock.
Other equities analysts also recently issued reports about the stock. Liberum Capital restated a buy rating and issued a GBX 5,500 ($72.58) target price on shares of AstraZeneca plc in a research note on Thursday, July 27th. Citigroup Inc. restated a buy rating on shares of AstraZeneca plc in a research note on Wednesday, July 5th. Kepler Capital Markets restated a buy rating and issued a GBX 5,500 ($72.58) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Deutsche Bank AG restated a buy rating and issued a GBX 5,700 ($75.22) target price on shares of AstraZeneca plc in a research note on Friday, July 28th. Finally, Investec upgraded shares of AstraZeneca plc from a hold rating to a buy rating and dropped their target price for the stock from GBX 5,000 ($65.98) to GBX 4,900 ($64.66) in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company’s stock. AstraZeneca plc has a consensus rating of Hold and a consensus price target of GBX 5,183.55 ($68.40).
AstraZeneca plc (LON AZN) opened at GBX 5,157.64 ($68.06) on Wednesday. AstraZeneca plc has a one year low of GBX 3,996 ($52.73) and a one year high of GBX 5,520 ($72.84).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
What are top analysts saying about AstraZeneca plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca plc and related companies.